Q3 Earnings Estimate for BPMC Issued By Wedbush
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities research analysts at Wedbush issued their Q3 2026 EPS estimates for Blueprint Medicines in a note issued to investors on Wednesday, April 16th. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings of $0.17 per share for the quarter. Wedbush has a “Outperform” […]
More Stories
DOJ Says It May Drop Boeing Criminal Fraud Case Over 737 Max Crashes
By Bill Pan The U.S. Department of Justice (DOJ) said it may drop its criminal prosecution of Boeing over allegations...
Milk, Science, and School Lunches: A Battle Over What Kids Eat
By Sherami Tsai Lawmakers are pushing to bring whole milk back to school cafeterias after it was banned in 2012. ...
Top Casino Stocks To Add to Your Watchlist – May 17th
Flutter Entertainment, DraftKings, Wynn Resorts, MGM Resorts International, and Churchill Downs are the five Casino stocks to watch today, according...
Focus Partners Wealth Grows Stock Position in Invesco Ltd. (NYSE:IVZ)
Focus Partners Wealth boosted its stake in shares of Invesco Ltd. (NYSE:IVZ – Free Report) by 66.8% during the 4th...
Janus Henderson Group PLC Has $3.43 Million Stock Holdings in H&R Block, Inc. (NYSE:HRB)
Janus Henderson Group PLC lifted its holdings in H&R Block, Inc. (NYSE:HRB – Free Report) by 3.2% in the 4th...
Focus Partners Wealth Buys Shares of 4,469 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Focus Partners Wealth bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the 4th quarter, according...